Tags

Type your tag names separated by a space and hit enter

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.
Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):774-776.CL

Authors+Show Affiliations

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. Electronic address: hyasuda@juntendo.ac.jp.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

32933879

Citation

Yasuda, Hajime, et al. "Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma." Clinical Lymphoma, Myeloma & Leukemia, vol. 20, no. 11, 2020, pp. 774-776.
Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(11):774-776.
Yasuda, H., Tsukune, Y., Watanabe, N., Sugimoto, K., Uchimura, A., Tateyama, M., Miyashita, Y., Ochi, Y., & Komatsu, N. (2020). Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clinical Lymphoma, Myeloma & Leukemia, 20(11), 774-776. https://doi.org/10.1016/j.clml.2020.08.017
Yasuda H, et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(11):774-776. PubMed PMID: 32933879.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. AU - Yasuda,Hajime, AU - Tsukune,Yutaka, AU - Watanabe,Naoki, AU - Sugimoto,Kazuya, AU - Uchimura,Ayana, AU - Tateyama,Misa, AU - Miyashita,Yosuke, AU - Ochi,Yusuke, AU - Komatsu,Norio, Y1 - 2020/08/22/ PY - 2020/07/08/received PY - 2020/08/08/revised PY - 2020/08/17/accepted PY - 2020/9/17/pubmed PY - 2020/11/18/medline PY - 2020/9/16/entrez KW - Atypical presentation KW - CHOP KW - Coronavirus KW - Hematological malignancy KW - Obinutuzumab SP - 774 EP - 776 JF - Clinical lymphoma, myeloma & leukemia JO - Clin Lymphoma Myeloma Leuk VL - 20 IS - 11 SN - 2152-2669 UR - https://www.unboundmedicine.com/medline/citation/32933879/Persistent_COVID_19_Pneumonia_and_Failure_to_Develop_Anti_SARS_CoV_2_Antibodies_During_Rituximab_Maintenance_Therapy_for_Follicular_Lymphoma_ DB - PRIME DP - Unbound Medicine ER -